Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase

References

• Ardelt, W.; Mikulski, S M.; Shogen, K. Amino acid sequence of an anti—tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases.J. Biol. Chem. 1991, 266, 245–251. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Leland, P A.; Raines, R T. Cancer chemotherapy–ribonucleases to the rescue.Chem. Biol. 2001, 8, 405–413. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Narayan, M.; Ku, G.; Ripoll, D R.; Zhai, H.; Breuker, K.; Wanjalla, C.; Leung, H J.; Navon, A.; Welker, E.; McLafferty, F W.; Scheraga, H A. Dissimilarity in the reductive unfolding pathways of two ribonuclease homologues.J. Mol. Biol. 2004, 338, 795–809. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lin, J.; Newton, D.; Mikulski, S.; Kung, H F.; Youle, R.; Rybak, S. Characterization of the mechanism of cellular and cell free protein synthesis inhibition by an anti-tumor ribonuclease.Biochem. Biophys. Res. Commun. 1994, 204, 156–162. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Iordanov, M S.; Ryabinina, O P.; Wong, J.; Dinh, T.-H.; Newton, D L.; Rybak, S M.; Magun, B E. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis.Cancer Res. 2000, 60, 1983–1994. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wu, Y.; Mikulski, S.; Ardelt, W.; Rybak, S.; Youle, R. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity.J. Biol. Chem. 1993, 268, 10686–10693. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Iwadate, Y.; Fujimoto, S.; Tagawa, M.; Namba, H.; Sueyoshi, K.; Hirose, M.; Sakiyama, S. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas.Int. J. Cancer 1996, 69, 236–240. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gao, C F.; Ren, S.; Zhang, L.; Nakajima, T.; Ichinose, S.; Hara, T.; Koike, K.; Tsuchida, N. Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis.Exp. Cell Res. 2001, 265, 145–151. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Spalletti-Cernia, D.; Sorrentino, R.; Di Gaetano, S.; Arcielo, A.; Garbi, C.; Piccoli, R.; D'Alessio, G.; Vecchio, G.; Laccetti, P.; Santoro, M. Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis.J. Clin. Endocrinol. Metab. 2003, 88, 2900–2907. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lee, I.; Lee, Y H.; Mikulski, S M.; Lee, J.; Covone, K.; Shogen, K. Tumoricidal effects of onconase on various tumors.J. Surg. Oncol. 2000, 73, 164–171. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Halicka, D H.; Juan, G.; Ardelt, B.; Mittelman, A.; Ardelt, W.; Mikulski, S.; Darzynkiewicz, Z. Induction of differentiation and apoptosis of U937 and HL-60 cells by Onconase: potentiation by inhibitors of protein kinases.Proc. Am. Soc. Clin. Oncol. 1996, 15, 18 ( Abst.). [CSA]
   Google Scholar
• Darzynkiewicz, Z.; Carter, S P.; Mikulski, S M.; Ardelt, W J.; Shogen, K. Cytostatic and cytotoxic effects of Pannon (P-30 protein), a novel anticancer agent.Cell Tissue Kinet. 1988, 21, 169–182. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Halicka, H D.; Murakami, T.; Papageorgio, C N.; Mittelman, A.; Mikulski, S M.; Shogen, K.; Darzynkiewicz, Z. Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP JCA-1) cells potentiates apoptosis triggered by onconase.Cell Prolif. 2000, 33, 407–417. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kreitman, R J.; Hansen, H J.; Jones, A L.; FitzGerald, D J.; Goldenberg, D M.; Pastan, I. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.Cancer Res. 1993, 53, 819–825. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rybak, S M.; Pearson, J W.; Fogler, W E.; Volker, K.; Spence, S E.; Newton, D L.; Mikulski, S M.; Ardelt, W.; Riggs, C W.; Kung, H F.; Longo, D L. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.J. Natl. Cancer Inst. 1996, 88, 747–753. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Juan, G.; Ardelt, B.; Li, X.; Mikulski, S M.; Shogen, K.; Ardelt, W.; Mittelman, A.; Darzynkiewicz, Z. G1 arrest of U93 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation.Leukemia 1998, 12, 1241–1248. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lazebnik, Y A.; Kaufmann, S H.; Desnoyers, S.; Poirier, G G.; Earnshaw, W C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE.Nature 1994, 371, 346–347. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mikulski, S M.; Ardelt, W.; Shogen, K.; Bernstein, E H.; Menduke, H. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos.J. Natl. Cancer Inst. 1990, 82, 151–153. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lee, I.; Lee, Y H.; Mikulski, S M.; Shogen, K. Effect of ONCONASE ± tamoxifen on ASPC-1 human pancreatic tumors in nude mice.Adv. Exp. Med. Biol. 2003, 530, 187–196. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mikulski, S.; Grossman, A.; Carter, P.; Shogen, K.; Costanzi, J. Phase I human clinical trial of Onconase (P-30 Protein) administered intravenously on a weekly schedule in cancer patients with solid tumors.Int. J. Oncol. 1993, 3, 57–64. [CSA]
   PubMed Web of Science ®Google Scholar
• Mikulski, S M.; Costanzi, J J.; Vogelzang, N J.; McCachren, S.; Taub, R N.; Chun, H.; Mittelman, A.; Panella, T.; Puccio, C.; Fine, R.; Shogen, K. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.J. Clin. Oncol. 2002, 20, 274–281. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Puccio, C.; Mittelman, A.; Chun, H.; Costanzi, J.; Panella, T.; Coombe, N.; Shogen, K.; Mikulski, S. A new anticancer Rnase (onconase): clinical trial in patients (pts) with breast cancer (BC).Proc. Am. Soc. Clin. Oncol. 1996, 15, 242 ( Abst.). [CSA]
   Google Scholar
• Vogelzang, N J.; Aklilu, M.; Stadler, W M.; Dumas, M C.; Mikulski, S M. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.Invest. New Drugs 2001, 19, 255–260. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mikulski, S.; Chun, H.; Mittelman, A.; Panella, T.; Puccio, C.; Shogen, K.; Costanzi, J. Relationship between response rate and median survial in patients with advanced nonsmall cell lung cancer: comparison of ONCONASE with other cancer agents.Int. J. Oncol. 1995, 6, 889–897. [CSA]
   PubMed Web of Science ®Google Scholar
• Herndon, J E.; Green, M R.; Chahinian, A P.; Corson, J M.; Suzuki, Y.; Vogelzang, N J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.Chest 1998, 113, 723–731. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alberts, A S.; Falkson, G.; van Zyl, L. Ifosfamide and mesna with doxorubicin have activity in malignant mesothelioma.Eur. J. Cancer 1990, 26, 1002. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ardizzoni, A.; Rosso, R.; Salvati, F.; Fusco, V.; Cinquegrana, A.; De Palma, M.; Serrano, J.; Pennucci, M C.; Soresi, E.; Crippa, M.; , et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) phase II study.Cancer 1991, 67, 2984–2987. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Baas, P.; van Meerbeeck, J.; Groen, H.; Schouwink, H.; Burgers, S.; Daamen, S.; Giaccone, G. Caelyx in malignant mesothelioma: a phase II EORTC study.Ann. Oncol. 2000, 11, 697–700. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ball, D.; Cruickshank, D. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy.Am. J. Clin. Oncol. 1990, 13, 4–9. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bretti, S.; Berruti, A.; Dogliotti, L.; Castagneto, B.; Bertulli, R.; Spadaro, P.; Toscano, G.; Astorre, P.; Verusio, C.; Lionetto, R.; Bruzzi, P.; Santoro, A. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors.Tumori 1998, 84, 558–561. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Carmichael, J.; Cantwell, B M.; Harris, A L. A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma.Eur. J. Cancer Clin. Oncol. 1989, 25, 911–912. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Chahinian, A P.; Antman, K.; Goutsou, M.; Corson, J M.; Suzuki, Y.; Modeas, C.; Herndon, J E., II; Aisner, J.; Ellison, R R.; Leone, L.; , et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.J. Clin. Oncol. 1993, 11, 1559–1565. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dirix, L Y.; van Meerbeeck, J.; Schrijvers, D.; Corthouts, B.; Prove, A.; van Marck, E.; Vermeire, P.; van Oosterom, A T. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.Ann. Oncol. 1994, 5, 653–655. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Harvey, V J.; Slevin, M L.; Ponder, B A.; Blackshaw, A J.; Wrigley, P F. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.Cancer 1984, 54, 961–964. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Henss, H.; Fiebig, H H.; Schildge, J.; Arnold, H.; Hasse, J. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.Onkologie 1988, 11, 118–120. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kosty, M P.; Herndon, J E., II; Vogelzang, N J.; Kindler, H L.; Green, M R. High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study–Cancer and Leukemia Group B 9631.Lung Cancer 2001, 34, 289–295. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lerner, H J.; Schoenfeld, D A.; Martin, A.; Falkson, G.; Borden, E. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience.Cancer 1983, 52, 1981–1985., [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Magri, M D.; Veronesi, A.; Foladore, S.; De Giovanni, D.; Serra, C.; Crismancich, F.; Tuveri, G.; Nicotra, M.; Tommasi, M.; Morassut, S.; , et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)—Mesothelioma Committee.Tumori 1991, 77, 49–51. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Magri, M D.; Foladore, S.; Veronesi, A.; Serra, C.; Nicotra, M.; Tommasi, M.; Grandi, G.; Monfardini, S.; Bianchi, C. Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study.Ann. Oncol. 1992, 3, 237–238. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mattson, K.; Giaccone, G.; Kirkpatrick, A.; Evrard, D.; Tammilehto, L.; van Breukelen, F J.; Planteydt, H T.; van Zandwijk, N. Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.J. Clin. Oncol. 1992, 10, 824–828. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Oh, Y.; Perez-Soler, R.; Fossella, F V.; Glisson, B S.; Kurie, J.; Walsh, G L.; Truong, M.; Shin, D M. Phase II study of intravenous Doxil in malignant pleural mesothelioma.Invest. New Drugs 2000, 18, 243–245. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Parra, H S.; Tixi, L.; Latteri, F.; Bretti, S.; Alloisio, M.; Gravina, A.; Lionetto, R.; Bruzzi, P.; Dani, C.; Rosso, R.; Cosso, M.; Balzarini, L.; Santoro, A.; Ardizzoni, A. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).Cancer 2001, 92, 650–656. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pennucci, M C.; Ardizzoni, A.; Pronzato, P.; Fioretti, M.; Lanfranco, C.; Verna, A.; Giorgi, G.; Vigani, A.; Frola, C.; Rosso, R. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.Cancer 1997, 79, 1897–1902. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Samson, M K.; Wasser, L P.; Borden, E C.; Wanebo, H J.; Creech, R H.; Phillips, M.; Baker, L H. Randomize comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.J. Clin. Oncol. 1987, 5, 86–91. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shin, D M.; Fossella, F V.; Umsawasdi, T.; Murphy, W K.; Chasen, M H.; Walsh, G.; Komaki, R.; McMurtrey, M J.; Hong, W K. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.Cancer 1995, 76, 2230–2236. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Skubitz, K M. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.Cancer Investig. 2002, 20, 693–699. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sorensen, P G.; Bach, F.; Bork, E.; Hansen, H H. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.Cancer Treat. Rep. 1985, 69, 1431–1432. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Tsavaris, N.; Primikirios, N.; Mylonakis, N.; Varouchakis, G.; Dosios, T.; Pavlidis, N.; Skarlos, D.; Tasopoulos, T.; Dritsas, J.; Kosmidis, P. Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective].Anticancer Res. 1997, 17, 3782–3799. [CSA]
   Google Scholar
• Upham, J W.; Musk, A W.; van Hazel, G.; Byrne, M.; Robinson, B W. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.Aust. N. Z. J. Med. 1993, 23, 683–687. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Yap, B S.; Benjamin, R S.; Burgess, M A.; Bodey, G P. The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma.Cancer 1978, 42, 1692–1696. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mikulski, S.; Newton, D.; Wiltrout, R.; Rybak, S. Onconase and doxorubicin synergy in prolonging survival of MDA-MB-231 human breast cancerbearing nude mice.Proc. Am. Assoc. Cancer Res. 1999, 40, 491 ( Abst.). [CSA]
   Google Scholar
• Senderowicz, A M.; Vitetta, E.; Headlee, D.; Ghetie, V.; Uhr, J W.; Figg, W D.; Lush, R M.; Stetler-Stevenson, M.; Kershaw, G.; Kingma, D W.; Jaffe, E S.; Sausville, E A. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.Ann. Intern. Med. 1997, 126, 882–885. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Newton, D L.; Hansen, H J.; Mikulski, S M.; Goldenberg, D M.; Rybak, S M. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.Blood 2001, 97, 528–535. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Newton, D L.; Hansen, H J.; Liu, H.; Ruby, D.; Iordanov, M S.; Magun, B E.; Goldenberg, D M.; Rybak, S M. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.Crit. Rev. Oncol./Hematol. 2001, 39, 79–86. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Spalletti-Cernia, D.; Sorrentino, R.; Di Gaetano, S.; Piccoli, R.; Santoro, M.; D'Alessio, G.; Laccetti, P.; Vecchio, G. Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin.Br. J. Cancer 2004, 90, 270–277. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Adams, J. The development of proteasome inhibitors as anticancer drugs.Cancer Cell 2004, 5, 417–421. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar